Protagenic Therapeutics, Inc.\new Marketable Securities, Unrealized Gain (Loss)
Protagenic Therapeutics, Inc.\new (PTIX) reported Marketable Securities, Unrealized Gain (Loss) of $26.59 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2025-03-31
- Protagenic Therapeutics, Inc.\new marketable securities, unrealized gain (loss) for the quarter ending 2024-12-31 was $0.00.
- Protagenic Therapeutics, Inc.\new marketable securities, unrealized gain (loss) for the quarter ending 2024-09-30 was $0.00.
- Protagenic Therapeutics, Inc.\new marketable securities, unrealized gain (loss) for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new marketable securities, unrealized gain (loss) for the quarter ending 2024-03-31 was $26.59K, a 44.24% decline year-over-year.
- Protagenic Therapeutics, Inc.\new marketable securities, unrealized gain (loss) for fiscal 2024 was $26.59K, a 57.81% increase from fiscal 2023.
- Protagenic Therapeutics, Inc.\new marketable securities, unrealized gain (loss) for fiscal 2023 was $16.85K, a 96.01% decline from fiscal 2022.
- Protagenic Therapeutics, Inc.\new marketable securities, unrealized gain (loss) for fiscal 2022 was $421.74K.
- Protagenic Therapeutics, Inc.\new marketable securities, unrealized gain (loss) for fiscal 2019 was $4.82K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $26.59K 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $26.59K 10-Q · filed 2024-11-14 | -$12.07K derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | $26.59K 10-Q · filed 2024-08-14 | -$12.07K derived: sum of 3 quarters · filed 2024-08-14 | -$46.53K derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | $26.59K 10-Q · filed 2024-05-15 | -$12.07K derived: sum of 2 quarters · filed 2024-05-15 | -$46.53K derived: sum of 3 quarters · filed 2024-05-15 | -$4.24K derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | -$38.66K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-05-14 | -$73.12K derived: sum of 2 quarters · filed 2024-05-14 | -$30.83K derived: sum of 3 quarters · filed 2024-05-14 | $16.85K 10-K/A · filed 2024-05-14 |
| 2023-09-30 | -$34.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $7.83K derived: sum of 2 quarters · filed 2023-11-14 | $55.50K 10-Q · filed 2023-11-14 | $116.74K derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | $42.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $89.97K 10-Q · filed 2023-08-14 | $151.20K derived: sum of 3 quarters · filed 2023-08-14 | |
| 2023-03-31 | $47.68K 10-Q · filed 2023-05-15 | $108.92K derived: sum of 2 quarters · filed 2023-05-15 | ||
| 2022-12-31 | $61.24K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $421.74K 10-K · filed 2023-03-31 | ||
| 2022-09-30 | $360.50K 10-Q · filed 2022-11-14 | |||
| 2021-09-30 | -$974.00 10-Q · filed 2021-11-15 | |||
| 2019-12-31 | $4.82K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |